The effects of food and divided dosing on the bioavailability of oral vinorelbine

Cancer Chemotherapy and Pharmacology

Volumn 39, Issue 1-2, 1996, Pages 9-16

  Rowinsky, Eric K ^a,c   Lucas, V Sol ^b   Hsieh, Ai Ly Y ^b   Wargin, William A ^b   Hohneker, John A ^b   Lubejko, Barbara ^a   Sartorius, Susan E ^a   Donehower, Ross C ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Burroughs Wellcome Co   (United States)

^c CTRC Institute for Drug Development   (United States)

Author keywords

Bioavailability; Divided dosing; Food; Navelbine; Oral; Pharmacokinetics; Vinorelbine

Indexed keywords

GELATIN; NAVELBINE; VINCA ALKALOID;

ADULT; AGED; ARTICLE; BIOAVAILABILITY; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIET RESTRICTION; DOSE RESPONSE; DRUG SAFETY; FEMALE; FOOD DRUG INTERACTION; GASTROINTESTINAL TRANSIT; HUMAN; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR; VOMITING;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CAPSULES; DRUG ADMINISTRATION SCHEDULE; FASTING; FEMALE; FOOD; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RANDOM ALLOCATION; VINBLASTINE;

EID: 0029820708     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050532     Document Type: Article

References (27)

1. Rowinsky EK, Donehower RC (1991) The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmacol Ther 52:35-84
2. Armand JP, Marty M (1989) Navelbine: a new step in cancer therapy. Semin Oncol 16 [Suppl 4]:41-45
3. Sorensen JB (1992) Vinorelbine. A review of its antitumour activity in lung cancer. Drugs 44 [Suppl 4]:60-65
4. Cvitkovic E, Izzo J (1992) The current and future place of vinorelbine in cancer therapy. Drugs 44 [Suppl 4]:36-45
5. Marty M, Extra JM, Dieras V, Giacchetti S, Ohana S, Espie M (1992) A review of the antitumour activity of vinorelbine in breast cancer. Drugs 44 [Suppl 4]:29-35
6. Spielmann M, Dorval T, Turpin F, Antoine E, Jouve M, Maylevin F, Lacombe D, Rouesse J, Pouillart P, Tursz T, Merle, S (1994) Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer. J Clin Oncol 12:1764-1770
7. Budman DR (1992) New vinca alkaloids and related compounds. Semin Oncol 19:639-645
8. Potier P (1989) The synthesis of Navelbine prototype of a new series of vinblastine derivatives. Semin Oncol 16 [Suppl 4]:2-4
9. Fellous A, Ohayon R, Vacassin T, Binet S, Lataste H, Krikorian A, Couzinier JP, Meninger V (1989) Biochemical effects of Navelbine on tubulin and associated proteins. Semin Oncol 16 [Suppl. 4]:9-14
10. Binet S, Fellous A, Lataste H, Krikorian A, Couzinier JP, Meninger V (1989) In situ analysis of the action of Navelbine on various types of microtubules using immunofluorescence. Semin Oncol 16 [Suppl 4]:5-8
11. Binet S, Chaineau E, Fellous A, Krikorian A, Couzinier JP, Meninger V (1990) Immunoflourescence study of the action of Navelbine, vincristine, and vinblastine on mitotic and axonal microtubules. Int J Cancer 46:262-266
12. Hodes M, Rohn R, Bond W, Corpening WG, Yardley JM, (1961) Vincaleukoblastine III. Clinical trial with the oral preparation. Cancer Chemother Rep 14:129
13. Kreis W, Budman D, Schulman P, Freeman J, Griest A, Nelson RL, Marks M, Kevill L (1986) Clinical pharmacology of vinzolidine. Cancer Chemother Pharmacol 16:70-74
14. Taylor C, Salmon S, Satterlee W, et al (1990) A phase I and pharmacokinetic study of intravenous vinzolodine. Invest New Drugs 8:551-557
15. Rowinsky EK, Noe DA, Lucas VS, Winer E, Lucas VS, Wargin WA, Hohneker J, Lubejko B, Sartorius JE, Ettinger DJ, Douhower RC (1994) A phase I, pharmacokinetic and absolute bioavailability study of oral vinorelbine (Navelbine) in solid tumor patients. J Clin Oncol 12:1754-1763
16. Tam YK (1993) Individual variation in first-pass metabolism. Clin Pharmacokinet 25:300-325
17. National Cancer Institute (1988) Guidelines for reporting of adverse drug reactions. Division of Cancer Treatment, National Cancer Institute, Bethesda
18. Pinedo HM (1994) Vinorelbine: a horse of a different color? J Clin Oncol 12:1745-1747
19. D'Incalci MD, Bolis G, Mangoini C, Morasca L, Garattini S (1978) Variable oral absorption of hexamethylmelamine in man. Cancer Treat Rep 62:173-175
20. Smyth R, Pfeffer M, Scalzo A, Comis RL (1985) Bioavailability and pharmacokinetics of etoposide (VP-16). Semin Oncol 12:48-51
21. Hande KR, Krozely MG, Greco A, Hainsworth JO, Johnson DH (1993) Bioavailability of low-dose etoposide. J Clin Oncol 11:374-377
22. Wagner T, Fenneberg K (1984) Pharmacokinetics and bioavailability of cyclophosphamide from oral formulations Arzneimittelforschung 34:313-314
23. Juma FD, Rogers HJ, Trounce JR (1979) Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration. Br J Clin Pharmacol 8:209-217
24. Shepherd AMM, Irvine NA, Ludden TM (1984) Effect of food on blood hydralazine levels and response in hypertension. Clin Pharmacol Ther 36:14-18
25. Semple HA, Koo W, Tam YK, Ngo LY, Coutts RT (1991) Interactions between hydralazine and oral nutrients in humans. Ther Drug Monit 13:304-308
26. Rowland M, Tozer TN (1989) Clinical pharmacokinetics, 2nd edn. Lea and Febiger, Philadelphia, pp 392-393
27. Leveque D, Merle-Melet M, Bresler L, Didelot JP, Aymard JP, Wihlm J, Jenl F (1993) Biliary elimination and pharmacokinetics of vinorelbine in micropigs. Cancer Chemother Pharmacol 32:486-490